Elutia Q4 revenue $3.3M (+16% YoY); NXT-41 510(k) submitted; cash $36.4M

ELUTIA INC.

Q4 2025 net sales from continuing ops $3.3M, up 16% YoY; adjusted gross margin 66.8%.
Full year net sales $12.3M; net loss from continuing ops $15.9M; net income $53.4M includes gain on BioEnvelope sale.
Submitted 510(k) for NXT-41 base biologic matrix to FDA; clearance expected H2 2026; full NXT-41x clearance in 1H27.
Closed $88M BioEnvelope sale to Boston Scientific; repaid $26.9M debt; cash $36.4M plus $8M escrow.
Initiated strategic review for SimpliDerm product line to focus on NXT-41x launch.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ELUTIA INC. reported the fourth quarter ended December 31, 2025 results: revenue $3.3 million, net income $70.8 million.

Period: the fourth quarter ended December 31, 2025
Revenue: $3.3 million
Net income: $70.8 million
Result: reported results

Exact text from the filing

and exclude the divested BioEnvelope business. For the three-month period ended December 31, 2025, as compared to the same period of 2024: • Overall net sales were $3.3 million, compared to $2.8 million in Q4 2024, an increase of 16%. • Net sales of SimpliDerm were $2.1 million, compared to $2.3 million in Q4 2024. • Net sales of Cardiovascular products

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ELUTIA INC. reported the year ended December 31, 2025 results: revenue $12.3 million, net income $53.4 million.

Period: the year ended December 31, 2025
Revenue: $12.3 million
Net income: $53.4 million
Result: reported results

Exact text from the filing

continuing operations and exclude the divested BioEnvelope business. For the year ended December 31, 2025, as compared to the same period of 2024: • Overall net sales were $12.3 million, compared to $14.5 million, reflecting the changes in the SimpliDerm and cardiovascular distribution models. • Net sales of SimpliDerm were $9.1 million, compared to $11.6

View on SEC.gov

Browse all earnings releases →

ELUTIA INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-026398

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.